HBV通过丙酮酸依赖性活性氧生成诱导肝纤维化
本研究探讨HBV诱导肝纤维化的机制,提出丙酮酸-PPARα-活性氧通路假说。在多种细胞和小鼠模型中,HBV感染增加丙酮酸并抑制PPARα,导致ROS生成和促纤维化基因表达上调;抑制ROS或激活PPARα可阻断纤维化。丙酮酸和PPARα可能成为抗纤维化治疗新靶点。
要点
- HBV感染增加丙酮酸水平并抑制PPARα表达,促进ROS生成和肝纤维化。
- 激活PPARα或抑制ROS可阻断HBV诱导的促纤维化基因表达。
- 丙酮酸和PPARα是慢性乙型肝炎抗纤维化治疗的潜在新靶点。
核心结论
- HBV感染通过增加丙酮酸生成和降低PPARα表达,导致ROS生成增加,进而诱导肝纤维化。
研究设计与样本
- 研究在HepAD38、HBV感染的NTCP-HepG2、原代人肝细胞和HSC系(LX2)的單培养和共培养模型及患者血清中评估HBV诱导的纤维化。
- 研究还在细胞培养、HBV携带小鼠、HBV转基因小鼠、人源化肝脏小鼠和人精密切割肝切片模型中评估PPARα激动剂/拮抗剂和ROS抑制对HBV诱导肝纤维化的影响。
主要发现
- HBV增加HBV感染肝细胞和患者血清中的丙酮酸水平及纤维化相关基因表达。
- HBV感染细胞上清和丙酮酸补充独立且叠加地增加促纤维化基因(TGF-β1、TIMP-1、COL1A1和α-SMA)表达,激活ROS产生并抑制PPARα表达。
- PPARα抑制和siRNA敲低增加ROS产生和促纤维化基因表达,而PPARα激活阻断HBVsup诱导和丙酮酸诱导的ROS生成及纤维化。
- ROS抑制可消除HBVsup诱导、丙酮酸补充诱导或PPARα抑制诱导的肝纤维化,证实ROS位于PPARα相关纤维化下游。
临床怎么用
- 丙酮酸和PPARα可作为慢性乙型肝炎抗纤维化治疗开发的新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Chronic hepatitis B (CHB) is a major etiology of liver cirrhosis. We previously found that pyruvate, a key intermediate in many metabolic pathways, increases HBV replication. However, the mechanism by which pyruvate mediates HBV-induced liver fibrosis is not well characterized. We hypothesize that HBV induces liver fibrosis through a pyruvate-peroxisome proliferator-activated receptor α (PPARα)-reactive oxygen species (ROS) pathway. APPROACH AND RESULTS: We evaluated HBV-induced fibrogenesis in HepAD38, HBV-infected NTCP-HepG2, primary human hepatocytes (PHHs), and HSC lines (LX2) in mono-culture and co-culture models and in patient sera. We also evaluated the effects of PPARα agonist/antagonist and ROS inhibition on HBV-induced liver fibrosis in cell culture, HBV carrier mouse, HBV-Transgenic mouse (HBV-Tg), humanized liver mouse, and human precision-cut liver slice (PCLS) models. We found that HBV increased pyruvate levels and fibrosis-related gene expression in both HBV-infected hepatocytes and patient sera. Supernatants from HBV-infected cells (HBVsup) and pyruvate supplementation independently and additively increased expression of profibrotic genes (TGF-β1, TIMP-1, COL1A1, and α-SMA), activated ROS production, and inhibited PPARα expression. Notably, PPARα inhibition and siRNA knockdown increased ROS production and profibrogenic gene expression, while activation of PPARα blocked HBVsup-induced and pyruvate-induced ROS generation and fibrogenesis. ROS was confirmed to be downstream of PPARα-related fibrogenesis, as ROS inhibition abrogated HBVsup-induced, pyruvate supplementation-induced, or PPARα inhibition-induced liver fibrosis. CONCLUSIONS: HBV infection induces pyruvate production and decreases PPARα expression, leading to increased ROS generation and liver fibrosis. Pyruvate and PPARα represent novel targets for antifibrotic therapeutic development in CHB.
引用
- Duan X, Li S, Li Q, et al. HBV induces liver fibrosis through the generation of reactive oxygen species in a pyruvate-dependent manner. Hepatology. 2025. PMID: 41295898. doi:10.1097/HEP.0000000000001597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。